Type to search

Antonino Nicoletti

Share
Antonino Nicoletti
Scientific Founders
Tridek-One SAS

Antonino Nicoletti

Professor and head of the doctoral school in Immunology at the University Paris Cité, Antonino leads the Laboratory for Vascular Translational Science, INSERM U1148, in Paris. Antonino Nicoletti obtained a PhD on inflammation in hypertension in Paris and performed a postdoc at the Karolinska Institute in Stockholm where he demonstrated that immune intervention on the humoral immunity can be harnessed to modulate atherogenesis. Hired as an Assistant Professor in Immunology at the University of Marie Curie (1998) he co-founded the ‘Immunopathology and therapeutic immunointervention’ Inserm laboratory (U681) with the Campus “Les Cordeliers”, in Paris and created a new team entitled ‘Cardiovascular Immunobiology’ in 2009 at the University Hospital Bichat. There he could make scientific contributions on the lymphoid neogenesis in the context of alloimmunity and of atherothrombosis.

Giuseppina Caligiuri and Antonino Nicoletti together filed 12 patents and co-founded Tridek-One in 2018 and Kapto Medical.

In the scope of the Tridek-One on-going collaboration with INSERM, Giuseppina and Antonino significantly contribute to the research and development of the Tridek-One CD31 research program.

Posts Featuring Antonino Nicoletti


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/class-wpdb.php on line 1562
Tridek-one Closes a €16 Million Financing Round to Develop First-in-class Immune Checkpoint Agonists | Pharmtech Focus

Tridek-one Closes a €16 Million Financing Round to Develop First-in-class Immune Checkpoint Agonists